Therapy focus – Opdivo and Livatag could add to liver cancer options
Investors interested in hepatocellular carcinoma are in for a busy month, with two phase III studies expected to render results. These are the closely watched Checkmate-459 trial of Bristol-Myers Squibb’s Opdivo used first-line and the Relive study testing Onxeo’s Livatag, a nanoparticle formulation of doxorubicin, in second or later-line settings.
Appetites have been whetted by early data at last week's Esmo World Congress on Gastrointestinal Cancer, and expectations are high for positive results with Opdivo, as the drug has shown activity in first and second-line hepatocellular carcinoma (HCC) in the earlier Checkmate-040 trial. On the basis of this, Bristol has already filed the anti-PD-1 MAb in the US for second-line use, seeking accelerated approval (see tables below).
That filing has an FDA action date of September 24, so Bristol will be hoping for an unambiguous PFS result in Checkmate-459. And, if it does subsequently obtain regulatory clearance, it could use the data both for a fast move to first-line status and as the confirmatory phase III study required with accelerated approval.
Head to head or sequenced?
Checkmate-459 is testing Opdivo head to head against Bayer’s Nexavar, though the crossover design means the overall survival comparison is likely to be more of a sequenced combination versus the kinase inhibitor alone. The trial has response rate and OS as co-primary endpoints, although survival data are not expected to become available until October 2018.
In the case of the Onxeo’s Relive, which tests two doses of Livatag, external expectations are more modest, despite the lower efficacy bar set by virtue of the study having best standard of care – effectively palliative care – as control.
However, after the recent approval of Stivarga for second-line HCC, Relive’s results will be have to match or beat those of the newer Bayer agent for Livatag to gain traction in the second-line setting. The Resorce phase III of Stivarga showed a 2.8-month survival advantage (Bayer quietly claims its liver cancer prize, June 29, 2016).
While Bayer’s commercial franchise in HCC has been strengthened by the approval of Stivarga, it is likely to come under pressure on both first and second fronts from new agents over the next year.
In the first-line setting this pressure will initially come from Eisai’s Lenvima, which may compete with Nexavar. Lenvima has just been filed for HCC in Japan, and Eisai expects to make EU and US filings by the end of September.
Results from the Japanese company’s Reflect phase III study, which were presented at Asco last month, met the statistical criteria for non-inferiority, the primary endpoint, but also showed significant benefits over Nexavar in terms of PFS, time to progression and response rate.
|Reflect study results|
|Endpoint||Lenvima (n=478)||Nexavar (n=476)||Statistics|
|Median OS||13.6 mth||12.3 mth||HR = 0.92, non-inferior|
|Median PFS||7.4 mth||3.7 mth||HR = 0.66, p<0.00001|
|Median time to progression||8.9 mth||3.7 mth||HR = 0.63, p<0.00001|
|Overall remission rate||24.1%||9.2%||p<0.00001|
Over the next nine months the HCC field will see three other phase III readouts, one of which is first line: the Phocus study of Sillagen/Transgene’s oncolytic virus Pexa-Vec will report in October. Phocus tests Pexa-Vec in combination with Nexavar and should provide an interesting comparison with Lenvima and Opdivo.
However, a separate trial seems to be anticipating the direction in which HCC is heading: Sillagen and Transgene recently announced plans for a phase I/II study to test Pexa-Vec in combination with Opdivo.
The other two near-term readouts are second line: Lilly’s Reach-2 study of Cyramza, recruiting patients with elevated alpha fetoprotein, and Exelixis’s Celestial trial of Cabometyx. Hopes are high for Cabometyx, and Exelixis and Bristol are testing the combination of this project with Opdivo with or without Yervoy in RCC and potentially HCC once the outcome of Celestial is known.
With Opdivo likely to become the backbone of HCC therapy, one question will be Merck & Co’s strategy in this indication, given that it is running two similar phase III studies, one in Asian patients, with second-line Keytruda.
These do not read out until 2019, and seem unlikely to offer much commercial traction if Opdivo first becomes established as a front-line treatment. Merck is also running a single-arm phase II study, Keynote-224, due to report data later this year.
There are of course numerous other studies of anti-PD-(L)1 agents testing the water in early trials for HCC. Astrazeneca is trialing Imflinzi and tremelimumab alone and in combination, while Novartis is testing PRD-001 alone and with the c-Met inhibitor capmatinib and with the anti-FGFR4 FGF401.
Beigene, which reported early data at the Esmo World Congress on Gastrointestinal Cancer, and Jiangsu HengRui are both conducting monotherapy studies in HCC with their respective anti-PD-1 MAbs BGB-A317 and SHR-1210.
Unless there is a major upset with Checkmate-459, HCC looks set to become an indication where the market, at least in terms of checkpoint inhibitors, is dominated by Opdivo. The question then will be with what agents this will be combined.
|Phase III trials in advanced hepatocellular carcinoma|
|Opdivo||Bristol-Myers Squibb||Checkmate-459||1L||NCT02576509||Jun 2017|
|Donafenib||Suzhou Zelgen||–||1L||NCT02645981||Feb 2019|